Mawdsleys and Meabco A/S have launched a Named Patient Supply program to allow Oncologists within the European Union (EU) to obtain access to BP-C1 on an unlicensed basis for the treatment of metastatic breast cancer and incurable pancreatic cancer.   BP-C1 is a new benzene-poly-carboxylic acids complex with cis-diammineplatinum (II)…

November 2014 saw the start of one of the largest CMU National Contract Waves.   Mawdsleys were proud to have been nominated for the biggest number of distribution agreements for this wave than any before. To ensure the new contract transition went as smoothly as possible, we provided hospitals with as…